Core Viewpoint - Dianthus Therapeutics, Inc. has successfully completed a public offering of 8,470,989 shares of common stock, raising approximately $719 million to support its clinical and preclinical development activities, as well as general corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $81.00 per share, with underwriters exercising an option to purchase an additional 1,157,407 shares [1]. - Pre-funded warrants were also offered, allowing certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering was conducted under a shelf registration statement that was declared effective on January 30, 2026, and included a related registration statement filed on March 10, 2026 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the company's clinical and preclinical development activities, enhance commercial readiness, and for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 7,313,582 shares of common stock at $81.00 per share, aiming to raise approximately $625 million before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering is expected to close on March 12, 2026, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,157,407 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on January 30, 2026 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3]. Group 4: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].

Core Viewpoint - Dianthus Therapeutics, Inc. has initiated a public offering of $400 million in common stock, with an additional option for underwriters to purchase up to $60 million more, aimed at advancing its clinical and preclinical development activities [1][2]. Group 1: Offering Details - The public offering consists of $400 million in shares of common stock or pre-funded warrants for certain investors [1]. - Underwriters will have a 30-day option to purchase an additional $60 million of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Company Background - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].

Dianthus Therapeutics Conference Call Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Focus**: Development of therapies for neuromuscular diseases, specifically CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) Key Points from the Call CAPTIVATE Trial Update - **Trial Type**: Ongoing single 2-part Phase 3 pivotal trial for claseprubart in CIDP aimed at supporting a BLA (Biologics License Application) in adults with CIDP [4][16] - **Interim Responder Analysis**: An early go decision was made based on the interim responder analysis, indicating a commitment to patients with severe neuromuscular diseases [2][12] - **Dosing**: Evaluating claseprubart at 300 mg, 2 mL every 2 weeks [3][4] Trial Design and Comparisons - **Part A**: Open label, where patients improve by at least 1 point on the NCAT score for 2 visits in a row can move to Part B [5][12] - **Comparison with ADHERE Trial**: CAPTIVATE allows refractory patients to enter, unlike ADHERE, which required patients to relapse before dosing [6][8] - **Response Rate Target**: Aiming for a 40%-50% responder rate based on previous data from riliprubart, with a target of 20 out of the first 40 patients completing Part A [11][12] Market Opportunity - **CIDP Market Size**: Estimated to be a multi-billion dollar market with around 40,000 patients in the U.S. alone [16][17] - **Unmet Needs**: High demand for more efficacious, better-tolerated, and convenient treatment options for CIDP patients [17][18] Safety Profile - **Safety Observations**: No concerning safety events recorded, including no clinical symptoms of autoimmune activation or study discontinuation for safety issues [13][49] Study Modifications - **Changes in Part B**: Dropping the 600 mg arm and increasing the responder target from 40% to 50%, resulting in a reduction of patients needed from 192 to 128 [14][104] - **Powering Assumptions**: The elimination of the 600 mg arm strengthens the power to show separation between treatment and placebo [104] Future Milestones - **Upcoming Trials**: Plans to initiate a Phase 3 trial in generalized myasthenia gravis (gMG) in mid-2026, with top-line results expected in the second half of 2028 [20][21] - **Financial Position**: Strong balance sheet with approximately $514 million in cash as of December 31, 2025, to fund operations into 2028 [21] Conclusion - **Overall Sentiment**: The company expressed strong confidence in the data observed so far, indicating that results exceeded expectations and highlighted the potential of claseprubart as a best-in-disease therapy for CIDP [22][113] Additional Insights - **Patient-Centric Trial Design**: The trial design is considered more patient-friendly compared to competitors, which may contribute to higher enrollment rates [65][66] - **Regulatory Alignment**: Confidence in the adequacy of the patient exposure database for regulatory purposes, with ongoing discussions with the FDA [108][109] This summary encapsulates the key points discussed during the Dianthus Therapeutics conference call, focusing on the CAPTIVATE trial, market opportunities, safety profiles, and future milestones.

Core Insights - Dianthus Therapeutics has made a GO decision in the Phase 3 CAPTIVATE trial for claseprubart, targeting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with an early achievement of 20 confirmed responders from less than 40 participants [1][5][6] - The company is set to initiate a Phase 3 trial for claseprubart in generalized Myasthenia Gravis (gMG) in mid-2026, with top-line results expected in the second half of 2028 [1][6][14] - Financial results for the year ending December 31, 2025, show a net loss of $162.3 million, with cash reserves of $514.4 million projected to sustain operations into 2028 [1][13][10] Clinical Development - Claseprubart is a monoclonal antibody designed to selectively inhibit the C1s protein, with a self-administered subcutaneous injection option [3][14] - The Phase 2 MoMeNtum trial for claseprubart in Multifocal Motor Neuropathy (MMN) is ongoing, with top-line results anticipated in the second half of 2026 [1][8] - DNTH212, another investigational product, is in a Phase 1 study with results expected in the second half of 2026 [1][9] Financial Overview - R&D expenses for 2025 were $145.6 million, up from $83.1 million in 2024, primarily due to increased clinical costs and headcount [13] - General and administrative expenses rose to $34.3 million in 2025 from $25.0 million in 2024, reflecting higher staffing costs [13] - The company reported a net loss per share of $4.20 for 2025, compared to $2.55 in 2024 [13][27]

Dianthus Therapeutics Conference Call Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Date**: February 12, 2026 - **Key Executives**: Marino Garcia (CEO), Ryan Savitz (CFO) Key Industry and Company Insights 1. Transformational Year - 2025 was a pivotal year for Dianthus, marked by the first patient data in myasthenia gravis (MG), which exceeded expectations [2][60] 2. Product Pipeline - **DNTH212**: In-licensed from Leads Biolabs, a bifunctional fusion protein targeting BDCA2 to reduce type I interferon and BAFF/APRIL, showing potential as a best-in-class product [2][3] - **Clasiprubart**: An active C1s inhibitor with promising phase 2 data for MG, with two major catalysts expected in 2026 [3][4] 3. Upcoming Catalysts - **CIDP Phase 3 Study**: Interim responder analysis for the first 40 patients is anticipated in Q2 2026, accelerated from H2 2026 due to strong recruitment [4][16] - **MMN Phase 2 Results**: Expected in the second half of 2026 [4] 4. Competitive Landscape - **Riliprubart**: A competitor from Sanofi, currently in phase 3 studies for CIDP. Dianthus aims to demonstrate at least equal efficacy with a more convenient dosing regimen [10][12] - **Empaciperbart**: Another competitor in MMN, with Dianthus expecting similar efficacy but with advantages in administration and safety [31][39] 5. Efficacy Expectations - For CIDP, Dianthus aims for a responder rate of 40%-50% in the interim analysis, comparable to riliprubart's phase 2 data [12][17] - The company is focusing on a dosing regimen that is more efficient, potentially reducing the number of injections required [12][15] 6. Market Potential - The U.S. market for MG is estimated at $5 billion, with potential growth to $20-$25 billion as biologics penetrate further [60] - Dianthus anticipates capturing 5%-10% of the MG market, translating to $2-$4 billion in sales [60][62] 7. Financial Health - Dianthus ended the year with $514 million in cash, sufficient to fund operations through 2028 and support upcoming milestones [64] 8. Safety and Regulatory Considerations - Concerns about drug-induced lupus (DIL) were addressed, emphasizing the reliability of data from clinical trials versus anecdotal reports [54][56] - The company is confident in the safety profile of its products, with no reported cases of DIL in clinical programs [56] 9. Commercial Strategy - Dianthus plans to leverage the convenience of its auto-injector and the absence of a box warning to differentiate its products in the market [41][44] 10. Recruitment and Trial Design - The company is focusing on efficient recruitment strategies and trial designs that allow for quicker results and better patient outcomes [16][20] Conclusion Dianthus Therapeutics is positioned for significant growth with a strong pipeline and strategic focus on efficacy, safety, and market penetration. The upcoming data releases and competitive advantages in product administration are critical to its success in the evolving biotech landscape.

Core Insights - Dianthus Therapeutics, Inc. (DNTH) shares experienced a significant increase of 9.9% to $52.76, with trading volume surpassing the average [1] - The rise in stock price is linked to positive investor sentiment regarding the company's clinical-stage pipeline candidates, claseprubart and DNTH212, aimed at treating various autoimmune conditions [2] Financial Performance - The company is projected to report a quarterly loss of $0.97 per share, reflecting a year-over-year decline of 19.8%, with expected revenues of $0.52 million, down 61% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating a lack of upward revisions in earnings estimates [4] Industry Context - Dianthus Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Royalty Pharma (RPRX) also operates, finishing the last trading session 1% higher at $40.11 [4] - Royalty Pharma's consensus EPS estimate for its upcoming report is $1.33, representing a year-over-year increase of 15.7%, with a Zacks Rank of 3 (Hold) [5]

Core Viewpoint - Dianthus Therapeutics is focused on developing innovative autoimmune therapeutics with a strong pipeline aimed at patient-friendly self-administration methods [3]. Group 1: Product Development - The company is advancing two clinical-stage autoimmune therapeutics, emphasizing their best-in-class potential and infrequent subcutaneous self-administration [3]. - The first program, claseprubart, is a potent classical pathway inhibitor with an 8-week half-life, targeting activated C1s, and has shown positive Phase II results in Myasthenia Gravis (MG) [4]. - Clinical proof of concept has been established for classical pathway inhibition in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) [4]. - The product is designed for convenience, utilizing a single self-administered 300-milligram 2-milliliter auto-injector, with dosing every two or four weeks [4]. Group 2: Clinical Trials - The second program, DNTH212, has recently commenced its Phase I clinical trials [5].

Dianthus Therapeutics FY Conference Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Focus**: Development of clinical-stage autoimmune therapeutics with a best-in-class pipeline targeting patient-friendly, infrequent subcutaneous self-administration [2][3] Key Products and Pipeline Clasibobart - **Description**: A potent classical pathway inhibitor with an eight-week half-life, targeting activated C1s - **Clinical Status**: Positive phase two results disclosed in September, with clinical proof of concept for classical pathway inhibition in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [2][4] - **Administration**: 300 mg, 2 ml autoinjector dosed every two or four weeks [3][5] - **Market Potential**: Targeting over 150,000 patients in the U.S. for MG, CIDP, and Multifocal Motor Neuropathy (MMN) [5][6] - **Efficacy Data**: Impressive results with 300 mg every two weeks showing robust, statistically significant efficacy across five measures in MG [6][9] - **Phase 3 Trial**: Discussions with the FDA ongoing, aiming for a trial comparing placebo, Clasibobart every two weeks, and every four weeks [11][12] DNTH212 - **Description**: A bispecific fusion protein targeting BDCA2 and BAFF/APRIL pathways - **Clinical Status**: Currently in phase 1 trials, with plans to prioritize indications such as Systemic Lupus Erythematosus (SLE) and dermatomyositis [25][26] Market Opportunities Myasthenia Gravis (MG) - **Market Size**: Approximately 100,000 patients in the U.S. with ACHR positive MG [5] - **Competitive Advantage**: Clasibobart's mechanism may provide superior efficacy compared to existing C5 inhibitors by preventing pro-inflammatory toxins [10][11] Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - **Market Need**: High unmet need due to limitations of current treatments like IVIG and FcRns [13][14] - **Efficacy Signals**: Clasibobart showed better efficacy than IVIG in patients refractory to standard treatments [14][15] Multifocal Motor Neuropathy (MMN) - **Market Size**: Estimated 10,000-15,000 patients in the U.S. with a high potential for a blockbuster product due to lack of competition [21][33] - **Competitive Landscape**: Clasibobart is positioned against Empasibobart, with superior potency and a more convenient administration route [22][24] Financial Position - **Cash Reserves**: Approximately $514 million, providing a runway into 2028 [27] Additional Insights - **Trial Design**: Clasibobart's trial design allows for immediate switching from IVIG to Clasibobart, which may yield higher responder rates compared to traditional methods [19][20] - **Market Strategy**: Emphasis on the potential for Clasibobart to be the most convenient and patient-friendly biologic in MG and CIDP [12][13] - **Investor Considerations**: The company highlights the importance of looking at actions and trial designs rather than just statements when evaluating potential success [31][32] Conclusion Dianthus Therapeutics is positioned to make significant advancements in the treatment of autoimmune diseases with its innovative therapies, particularly Clasibobart, which shows promise in multiple indications and has a strong clinical and market strategy. The upcoming phase 3 trial and interim analyses are critical milestones to watch for potential investment opportunities.

Group 1 - The company Valiant Biopharma-B (09887) announced that its self-developed candidate drug LBL-047 has received approval for clinical trials (IND) from the National Medical Products Administration (NMPA) of China on November 25, 2025 [1] - LBL-047 is the world's first bispecific fusion protein targeting both plasmacytoid dendritic cells (pDC) and B cells, with a unique mechanism of action that positions it as a first-in-class and best-in-class potential therapy [1] - The approved clinical trial is a double-blind, randomized, placebo-controlled, dose-escalation Phase I study assessing the safety, tolerability, and preliminary clinical efficacy of LBL-047 in healthy adults and patients with systemic lupus erythematosus (SLE) [1] Group 2 - On October 16, 2025, the company entered into an exclusive global partnership with Dianthus Therapeutics (NASDAQ: DNTH) to develop transformative therapies for severe autoimmune diseases, granting Dianthus exclusive global rights for the research, production, and commercialization of LBL-047 outside Greater China [2] - The collaboration aims to advance the global development of LBL-047 and maximize its clinical value and commercial potential [2]